Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
Immunotherapy using monoclonal antibodies targeting the PD-1/PD-L1 interaction has shown enormous success for various cancers. Despite their encouraging results in clinics, antibody-based checkpoint inhibitors have several limitations, such as poor tumor penetration. To address these limitations of...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2022-04-01
|
| Colección: | Frontiers in Immunology |
| Materias: | |
| Acceso en línea: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.838966/full |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|